ES2295352T3 - Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas. - Google Patents

Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas. Download PDF

Info

Publication number
ES2295352T3
ES2295352T3 ES02738123T ES02738123T ES2295352T3 ES 2295352 T3 ES2295352 T3 ES 2295352T3 ES 02738123 T ES02738123 T ES 02738123T ES 02738123 T ES02738123 T ES 02738123T ES 2295352 T3 ES2295352 T3 ES 2295352T3
Authority
ES
Spain
Prior art keywords
methyl
compound according
thiazol
ylcarbonyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02738123T
Other languages
English (en)
Spanish (es)
Inventor
Bernard Andre Lab. GlaxoSmithKline DUMAITRE
Romain Luc Marie Lab. GlaxoSmithKline GOSMINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2295352T3 publication Critical patent/ES2295352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES02738123T 2001-05-31 2002-05-29 Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas. Expired - Lifetime ES2295352T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0113233 2001-05-31
GBGB0113233.1A GB0113233D0 (en) 2001-05-31 2001-05-31 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2295352T3 true ES2295352T3 (es) 2008-04-16

Family

ID=9915638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02738123T Expired - Lifetime ES2295352T3 (es) 2001-05-31 2002-05-29 Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas.

Country Status (21)

Country Link
US (1) US6867225B2 (enExample)
EP (1) EP1392665B1 (enExample)
JP (1) JP2004532266A (enExample)
KR (1) KR20040007633A (enExample)
CN (1) CN1529698A (enExample)
AT (1) ATE377007T1 (enExample)
AU (1) AU2002312954B2 (enExample)
BR (1) BR0210077A (enExample)
CA (1) CA2448103A1 (enExample)
CO (1) CO5540299A2 (enExample)
CZ (1) CZ20033250A3 (enExample)
DE (1) DE60223245T2 (enExample)
ES (1) ES2295352T3 (enExample)
GB (1) GB0113233D0 (enExample)
HU (1) HUP0400056A2 (enExample)
IL (1) IL158818A0 (enExample)
MX (1) MXPA03010584A (enExample)
NO (1) NO20035316L (enExample)
PL (1) PL367215A1 (enExample)
WO (1) WO2002096894A1 (enExample)
ZA (1) ZA200308864B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
CA2495179A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
EP1535915A4 (en) 2002-09-06 2005-10-05 Takeda Pharmaceutical FURANOIC OR THIOPHENE DERIVATIVES AND THEIR MEDICAL USE
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
FR2882750B1 (fr) * 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
JP5225076B2 (ja) * 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
FR2901792A1 (fr) * 2006-06-06 2007-12-07 Negma Lerads Soc Par Actions S DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
JP5357894B2 (ja) 2008-12-01 2013-12-04 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AU2010288523A1 (en) 2009-08-26 2012-03-15 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6207422B1 (en) * 1998-04-17 2001-03-27 The Metrohealth System Protein that enhances expression of potassium channels on cell surfaces and nucleic acids that encode the same
AU6501499A (en) * 1998-09-29 2000-04-17 Johns Hopkins University, The Inducible genetic suppression of cellular excitability
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists

Also Published As

Publication number Publication date
ATE377007T1 (de) 2007-11-15
JP2004532266A (ja) 2004-10-21
PL367215A1 (en) 2005-02-21
MXPA03010584A (es) 2004-03-09
IL158818A0 (en) 2004-05-12
US20040176427A1 (en) 2004-09-09
DE60223245T2 (de) 2008-08-14
CZ20033250A3 (en) 2004-03-17
GB0113233D0 (en) 2001-07-25
EP1392665B1 (en) 2007-10-31
NO20035316D0 (no) 2003-11-28
KR20040007633A (ko) 2004-01-24
AU2002312954B2 (en) 2004-12-02
CO5540299A2 (es) 2005-07-29
BR0210077A (pt) 2004-06-22
US6867225B2 (en) 2005-03-15
HUP0400056A2 (hu) 2004-04-28
CA2448103A1 (en) 2002-12-05
NO20035316L (no) 2003-11-28
EP1392665A1 (en) 2004-03-03
ZA200308864B (en) 2005-02-14
CN1529698A (zh) 2004-09-15
DE60223245D1 (de) 2007-12-13
WO2002096894A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ES2295352T3 (es) Derivados de tiazol o de oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas con las mismas.
US6518290B1 (en) Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
KR100668026B1 (ko) 티아졸 및 옥사졸 유도체 및 그의 제약적 용도
AU2002312954A1 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
JP2004517100A (ja) ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
KR100859591B1 (ko) Ｈｐｐａｒ-알파 수용체의 옥사졸/티아졸-유도체 활성제
US7141591B2 (en) 1,2,4-oxadiazole derivatives as hPPAR alpha agonists
US20070167628A1 (en) Thiazole-2-carboxamide derivatives for use as hippar agonists in the treatment of i.a. dyslipidemia
HK1064367B (en) Oxazol/thiazol-derivatives activators of the hppar-alpha receptor